Crohn’s disease genotypes of patients in remission vs relapses after infliximab discontinuation

Table 1 Polymerase chain reaction primers used for genotyping

Genetic variant	Sense primers	Antisense primers
Arg702Trp	5’-CAT CTG AGA AGG CCC TGC TC(C/T)-3’	5’-CAG ACA CCA GCG GGC ACA-3’
Gly908Arg	5’-TTG GCC TTT TCA GAT TCT GG(G/C)-3’	5’-CCC CTC GTC ACC CAC TCT G-3’
Leu1007fs insC	Not available	Not available
IGR2060a1	5’-CTC ATT ACA TCC TTG CAA CCC T(G/C)-3’	5’-GAC ACA TGG TGT GAG CTC AGT CA-3’
IGR3081a1	5’-TCG CGT GAG TCC TAT TCT TTC T(T/G)-3’	5’-TTC ATA CTT CCA GCA GCG GG-3’

Table 2 Characteristics for Crohn’s disease patients still in remission and those who lost remission after discontinuing infliximab

Characteristic	Remaining in remission following discontinuing infliximab (n = 6)	Lost remission following discontinuing infliximab (n = 8)
Male:female (n)	4:2	4:4
Age of Crohn’s disease onset (yr), mean (range)	30 (14-47)	26 (15-38)
Current age (yr), mean (range)	53 (41-60)	41 (25-57)
Duration of disease prior to first infliximab infusion (yr), mean ± SD	15 ± 8.0	10.1 ± 11.3
Age at first infliximab infusion (yr), mean ± SD	45 ± 7.6	36 ± 11.1
Number of infusions, mean ± SD	5.7 ± 3.5	4.7 ± 1.7
Duration of infliximab treatment (mo), mean (range)	12 (3.6-36.2)	7.2 (1.5-15)
Duration of remission after infliximab stopped (yr), mean ± SD	8.1 ± 2.61	1.0 ± 0.62
Disease distribution, n (%)
Ileum	2 (33)	2 (25)
Ileo-colonic	3 (50)	4 (50)
Colon	1 (17)	2 (25)
Current medications in patients who lost remission, n
Adalimumab		4
Infliximab		2
Azathioprine alone		1
No Biological or immunosuppressive therapy3		1

¹All patients still remain in remission at the time of this study;

²Follow-up time from last dose of infliximab to either date of flare or last day of study (July 6, 2011), P < 0.001;

³This patient developed both basal cell and renal cell carcinoma.

Table 3 5q31 and nucleotide-binding oligomerization domain 2/caspase activation recruitment domain 15 variants in crohn’s disease patients still in remission and those who lost remission after discontinuing infliximab

Variant	Remaining in remission following discontinuing infliximab (n = 6)	Lost remission following discontinuing infliximab (n = 8)	Odds ratio	P value
Arg702Trp			1.50	1.00
Homozygous wild type, CC (%)	4 (67)	6 (75)
Heterozygous, CT (%)	2 (33)	2 (25)
Homozygous mutant, TT (%)	0	0
Gly908Arg			-	-
Homozygous wild type, GG (%)	6 (100)	8 (100)
Leu1007fs insC	2 (33)	2 (25)	1.50	1.00
IGR2060a1			1.67	1.00
Homozygous wild type, GG (%)	1 (17)	2 (25)
Heterozygous, GC (%)	3 (50)	2 (25)
Homozygous mutant, CC (%)	2 (33)	4 (50)
IGR3081a1			-	0.47
Homozygous wild type, TT (%)	0	2 (25)
Heterozygous, GT (%)	4 (66)	2 (25)
Homozygous mutant, GG (%)	2 (33)	4 (50)